NEW ORLEANS, Nov 15 (Reuters) - A new type of heart drug
developed by Medicines Co significantly lowered "bad"
LDL cholesterol in high-risk patients with no major safety
issues, according to data from a midstage trial that helped the
company identify the dose it will move into advanced testing.
Read more
No comments:
Post a Comment